Breaking News, Collaborations & Alliances

IDT Bolsters CRISPR Portfolio with SeQure Dx Licensing Deal

Agreement enables IDT to support cell and gene therapy developers through all phases of their CRISPR-based therapeutic programs.

Author Image

By: Charlie Sternberg

Associate Editor

Integrated DNA Technologies (IDT), a leader in CRISPR genome editing solutions, has inked a licensing agreement with SeQure Dx, a company focused on off-target analysis for preclinical and clinical gene modification customers, bolstering IDT’s complete CRISPR portfolio. The licensing agreement enables IDT to support cell and gene therapy developers through all phases of their CRISPR-based therapeutic programs by providing comprehensive off-target analysis services, powered by SeQure Dx’s GUI...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters